SlideShare uma empresa Scribd logo
1 de 11
Baixar para ler offline
Guide for conduction of nonclinical and
clinical studies for registration of alpha-
   interferon as biological product by
       comparability development
National Health Surveillance Agency | Anvisa




Guide for Conduction of Nonclinical and
   Clinical Studies for Registration of
 Alpha-Interferon as Biological Product
    by Comparability Development




                       Brasilia 2011
Copyright © 2011. National Health Surveillance Agency.
Partial or full reproduction of this works is allowed provided the source is mentioned. Legal deposit in the National Library,
according to Decree No. 1.825, dated December 20, 1907.
1st edition.



CEO                                         CEO’s Assistant
Dirceu Aparecido Brás Barbano               Luiz Roberto da Silva Klassmann

Directors                                   Directors’ Assistants
Jaime César de Moura Oliveira               Luciana Shimizu Takara
José Agenor Álvares da Silva                Neilton Araujo de Oliveira
Maria Cecília Martins Brito                 Luiz Armando Erthal

Head of Cabinet
Vera Maria Borralho Bacelar


General Drug Management
Norberto Rech


Safety & Efficacy Assessment Management
Laura Gomes Castanheira


Biological Product Registration Coordination
Marcelo Mário Matos Moreira


Direct participation: Brenda
Gomes Valente Bernardo Luiz
Moraes Mo reira Fanny
Nascimento Moura Flávia
Regina Souza Sobral Daniela
Marreco Cerqueira Juliana
Bertoli da Silva
Laura Gomes Castanheira Marcelo
Mário Matos Mo reira Marcos
Fernando Galves da Silva Maria
Fernanda Reis e Silva Thees
Neemias Silva de Andrade
Patrícia Ferrari Andreotti
Raimundo Nonato Vieira Júnior
Rodrigo Martins Bretas
Silmara Crisitane da Silveira


Elaboration and editing


AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA
SIA Trecho 5, Área Especial 57, Lote 200
71205-050, Brasilia –
Federal District
Phone: (61) 3462-6000
Home page: www.anvisa.gov.br
Table of contents



1 Introduction.................................................................................................................................................... 4


2 General Considerations ...................................................................................................................................4


3 Nonclinical studies.....................................................................................................................................5


4 Clinical studies ...........................................................................................................................................6
5 Immunogenicity ..........................................................................................................................................7


6 Indication Extrapolation..........................................................................................................................7


7 Pharmacovigilance Plan ..........................................................................................................................7


8 References .................................................................................................................................................8




Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability                            3
1
Introduction

This guide outlines the clinical and nonclinical requirements for registration of recombinant human alpha-interferon in Anvisa
[National Health Surveillance Agency] as biological product, using the route of individual development. The nonclinical section
deals with the pharmaco-toxicological requirements, and the clinical section addresses the requirements for pharmacokinetic,
pharmacodynamics, efficacy and safety studies, as well as pharmacovigilance aspects. Suggestions of nonclinical and clinical
protocols are also presented.

In this guide, we will bring general directions for the conduction of nonclinical and clinical studies for registration of recombinant
human alpha-interferon by comparability. However, if the researcher/institution is able to evidence the efficacy and safety of these drugs
through other scientific and technically more feasible studies, the data presented will be evaluated by ANVISA and the deviation
from the guide’s directions must always be justified.

This Guide will address only the requirements for nonclinical and clinical studies applicable for registration of recombinant human
alpha-interferon by comparability, being that the other items of the specific standards must be complied with for health registration
of the product.




2              General
considerations

Recombinant human alpha-interferon (2a a n d 2 b ) i s a known and well characterized protein made up of 165 amino acids.
The non-glycosylated protein has a molecular weight of approximately 19.240 Da. The protein contains two disulfide
bridges, one between the cysteine residues 1 and 98 and another between the cysteine residues 29 and 138. The sequence
contains potential O-glycosylation sites. Physical, chemical and biological methods are available for protein
characterization.

Recombinant human alpha-interferon is approved for different indications like hepatitis virus B and C, leukemia, lymphoma, renal
cell carcinoma and multiple myeloma and can be used separately or in combination with other drugs. Alpha-interferon can have
different pharmacodynamics effects. The importance of these pharmacodynamics effects in each one of the clinical applications is still
unknown. Generally, the use of alpha-interferon in oncology has reduced considerably and is being replaced by other treatments.

The dose and therapeutic scheme required to obtain the desired response vary greatly according to the different indications.

Alpha-interferon is normally used subcutaneously, although it can also be used intramuscularly or intravenously. Treatment with
alpha-interferon 2a and 2b is associated with different adverse reactions like fever, discomfort, fatigue, myalgia and can also be
associated with psychiatric, hematological and renal adverse events.

Therapy with alpha-interferon can lead to development of auto-antibodies. A variety of autoimmune disorders like problems in the
thyroid, rheumatoid arthritis, systemic erythematous lupus, neuropathies and vasculitis have been observed with the use of alpha-
interferon.

Both neutralizing and non-neutralizing antibodies were observed during use of alpha-interferon.

This guide does not address the quality requirements. For aspects related to quality, the principles are applied as set forth in the Guide
for conduction of the comparability exercise for registration of biological products by comparability and Resolution RDC No. 55/10
and its updates.

According to RDC 55/10, the comparer biological product (CBP) cited in this guide is recombinant human alpha-interferon
registered at Anvisa through presentation of a complete dossier.
4   Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability
3 Nonclinical studies

Before starting the clinical development, nonclinical studies must be conducted. The nonclinical studies must be comparative and
designed to detect differences in the pharmaco-toxicological response between the alpha-interferon to be registered and the CBP, and
not just to evaluate the response per se. The approach adopted must be fully justified in the nonclinical summary.



Pharmacodynamic studies

In vitro studies:
In order to compare the changes in the activity between the alpha-interferon to be registered and the CBP, one must provide data on a
series of comparative bioassays (bond with receptor, antiviral effect in cell culture, anti-proliferative effects in tumor cell lineages),
being that several of these assays will already be part of the quality dossier in the comparability exercise.



In vivo studies:
One must compare the in vivo pharmacodynamics activity of the alpha-interferon to be registered and of the CBP in:

          • a suitable animal pharmacodynamics model (e.g. evaluation of the effects on pharmacodynamics markers, like 2’-5’-
          oligoadenylate synthetase activity in the serum). If possible, these evaluations must be conducted as part of a toxicity
          study.

          and/
          or

          • suitable tumor animal model and/or

          • suitable antiviral animal model



Toxicology Studies
Data on at least one repeated dose toxicity study in relevant species must be provided. The study must have duration of at least 4
weeks.

Toxicokinetic studies must be conducted as part of the repeated dose toxicity study and must include evaluation of the antibody
formation potential.

Data on the local tolerance in at least one species must be provided. If possible, these local tolerance tests can be conducted as part of
a repeated-dose toxicity study.

E Pharmacological studies on safety, reproductive toxicology, mutagenicity and carcinogenicity are not routine requirements for the
nonclinical tests of a biological drug product containing recombinant human alpha-interferon.

For the case of nonclinical development, comparative studies must be conducted using the alpha-interferon elected as comparer product
(alpha-interferon registered at Anvisa through presentation of a complete dossier) and the alpha-interferon to be registered. At least
two relevant species should be used if available and local tolerance, acute toxicity and repeated dose toxicity studies must be
conducted. Comparative evaluation of pharmacokinetic, pharmacodynamics and immunogenicity (whenever possible) parameters are
also required.




Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability   5
4 Clinical studies


    Pharmacokinetic/Pharmacodynamic Studies
    The pharmacokinetic/pharmacodynamics properties of the alpha-interferon to be registered and of the CBP must be compared in a
    randomized, single-dose study in health volunteers. The primary pharmacokinetic parameters recommended are area under the curve
    (AUC) and the secondary parameters are Cmax, T1/2 and CL/F.

    The equivalence margins must be pre-specified and appropriately justified.



    Pharmacodynamic Studies:
    Different pharmacodynamics markers are available, like β2 microglobulin, neopterin and 2’-5’- oligoadenylate synthetase activity
    in the serum, which are relevant to measure the interaction between alpha-interferon and the immune system. The doses selected must
    be in the ascending linear region of the dose response curve. Even though the importance of these pharmacodynamics effects is still
    unknown in the different indications, a complete comparative evaluation after administration of epoetin alpha to be registered and the
    CBP can provide useful data.

    After conducting the necessary nonclinical studies with satisfactory results, the conduction of a Phase I, comparative, double-blind
    study is recommended with health volunteers and a wash-out period of 4 weeks. The aim of this study is comparison of the
    pharmacokinetic and pharmacodynamics parameters and gathering of preliminary safety data.



    Clinical Efficacy

    Study population
    The action mechanism of alpha-interferon includes a series of different unrelated effects.

    Demonstration of effect similarity between the product to be registered and the CBP is required. This can be done in a virgin
    population of treatment with hepatitis C (HCV), as outlined by the indication of the CBP. Other populations must be studied
    according to the indications desired.



    Study outlining and duration
    A parallel, randomized group study for comparison of the products for at least 48 weeks is recommended. The study must be double-
    blind at least up to the point in which the data from the primary analyses is generated. If this is not possible, a justification must be
    presented and all actions to eliminate possible biases must be clearly identified in the protocol.

    The posology (dose, administration route and administration methodology) must be the same as for the CBP. The alpha-interferon
    must be administered together with the standard treatment for hepatitis C used together with the CBP.

    The study must be outlined so as to allow conduction of the primary efficacy analysis in the twelfth week for all recruited patients. A
    homogeneous population is preferably recommended, for example, a single viral genotype. If a heterogeneous population is selected,
    stratification must be conducted according to the viral genotype.



    Outcomes
    Primary: virological response evaluated by the number of patients with absence of HCV RNA detection by quantitative PCR in the
    twelfth week. The methodology used and the cutoff applied must be justified. A decrease of 2 log in the viral growth must have a co-
    primary outcome.

    Secondary: virological response in the fourth week and at the end of treatment; sustained virological response (24 weeks after the end
    of treatment); changes in the hepatic biochemical parameters including levels of transaminase and morbidity.

6   Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability
Clinical safety
The safety data must be collected from the patients after repeated doses in a comparative study during the treatment period and
another period of 24 weeks of follow-up. The number of patients must be enough for comparison of the adverse effect profiles.
Evaluation of lab changes of immune-mediated disorders must be included. The safety profile between the alpha-interferon to be
registered and the CBP must be similar for the most common adverse events (fever, discomfort, alopecia, myalgia, leukopenia,
anemia and thrombocytopenia).

If the results of the Phase I Study are satisfactory, a Phase II/III study can be conducted to evaluate the efficacy and safety of the
alpha-interferon to be registered in relation to the comparer biological product. It must be a double-blind study to compare
non-inferiority or equivalence in patients with Hepatitis C and have minimum duration of 48 weeks. The primary outcome of
the study must be viral remission (evaluated through quantitative PCR) in the 24th week and the secondary outcomes will be
virological response in the 4th, 12th and 48th weeks (evaluated through quantitative PCR); biochemical parameters must also be
evaluated (including transaminases) and morbidity levels. Evaluation of safety (type, severity and incidence of adverse events)
and of immunogenicity must be done for the period of the study duration (48 weeks). In case of any significant finding in
relation to the safety and immunogenicity parameters, additional studies may be requested.




5 Immunogenicity

Comparative data on immunogenicity (levels of antibodies) must be collected during the study period and also during the 24-week
follow-up period. The antibodies, when present, must be evaluated for neutralizing capacity and potential impact on product efficacy.
Furthermore, any potential for neutralization of the alpha-interferon’s endogenous effect (development of autoimmunity) must be
evaluated. Any immunogenicity impact must be evaluated in patients who do not respond to the treatment, patients who present loss
of response in the primary treatment and patients who present unexpected adverse reactions or immune-mediated events.




6 Indication Extrapolation

At first, the extrapolation of therapeutic indications is possible when the action mechanism and/or receptors are the same for which the
clinical similarity was established, through comparative clinical study.




7 Pharmacovigilance Plan

Within the authorization procedure, the applicant must always present a pharmacovigilance plan and a risk reduction plan whenever
required according to the legislation in effect and pharmacovigilance guidelines.

Special attention must be paid to issues related to immunogenicity and later serious adverse effects in patients under chronic
administration of the product. Safety data must be gathered from patients covering all approved indications.

The Pharmacovigilance Plan must include follow-up of the patients included in the Phase II/III study for evaluation of relapses.



Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability   7
8 References

    Guideline on similar biological medicinal products (CHMP/437/04/draft).

    Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical
    and clinical issues (EMEA/CPMP/42832/05/draft).

    Note for guidance on repeated dose toxicity (CPMP/SWP/1042/99).

    Note for guidance on toxicokinetics: A Guidance for assessing systemic exposure in toxicological studies (CPMP/ICH/384/95).

    Note for guidance on non-clinical locale tolerance testing of medicinal products (CPMP/SWP/2145/00).

    Guideline on risk management systems for medicinal products for human use (EMEA/CHMP 96286/2005).

    Note for Guidance on Good Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/
    ICH/377/95).

    ICH Note for Guidance on Planning Pharmacovigilance Activities (CPMP/ICH/5716/03 - Final approval by CHMP on PHV).

    Guidance on Planning Pharmacovigilance Activities (CPMP/




8   Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability
Ministry of
  Health

Mais conteúdo relacionado

Mais procurados

Biological agents and it role in current era and future role
Biological agents and it role in current era and future roleBiological agents and it role in current era and future role
Biological agents and it role in current era and future roleHarsh shaH
 
Hepatoprotective and Antioxidant Effects of the Flavonoid-rich Fraction of th...
Hepatoprotective and Antioxidant Effects of the Flavonoid-rich Fraction of th...Hepatoprotective and Antioxidant Effects of the Flavonoid-rich Fraction of th...
Hepatoprotective and Antioxidant Effects of the Flavonoid-rich Fraction of th...IOSRJPBS
 
new drug development by harsha
new drug development by harshanew drug development by harsha
new drug development by harshaSriharsha Rayam
 
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...sstrumello
 
Biopharmaceuticals and biosimilar drugs
Biopharmaceuticals and biosimilar drugsBiopharmaceuticals and biosimilar drugs
Biopharmaceuticals and biosimilar drugsDr. Mohit Kulmi
 
Potential role of bioactive peptides in prevention and treatment of chronic d...
Potential role of bioactive peptides in prevention and treatment of chronic d...Potential role of bioactive peptides in prevention and treatment of chronic d...
Potential role of bioactive peptides in prevention and treatment of chronic d...NxFxProducerDJ
 
new biological targets by prathyusha .m
new biological targets by prathyusha .mnew biological targets by prathyusha .m
new biological targets by prathyusha .mpharmacologyseminars
 
Pegylation & biosimilars global scenario
Pegylation & biosimilars   global scenarioPegylation & biosimilars   global scenario
Pegylation & biosimilars global scenarioMalay Singh
 
Biosimilar : A Biologic Drug Revolution.
Biosimilar : A Biologic Drug Revolution.Biosimilar : A Biologic Drug Revolution.
Biosimilar : A Biologic Drug Revolution.Yogeshwary Bhongade
 
Biosimilars: A biologic drug revolution
Biosimilars: A biologic drug revolutionBiosimilars: A biologic drug revolution
Biosimilars: A biologic drug revolutionAbu Sufiyan Chhipa
 
Biosimilars ppt presentation
Biosimilars ppt presentationBiosimilars ppt presentation
Biosimilars ppt presentationmeghanamegha23
 
Development mol drug
Development mol drugDevelopment mol drug
Development mol drugswati2084
 
Biosimilars in rheumatology
Biosimilars in rheumatologyBiosimilars in rheumatology
Biosimilars in rheumatologymohammad ali
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and developmentrahul_pharma
 
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017Fight Colorectal Cancer
 

Mais procurados (20)

Biological agents and it role in current era and future role
Biological agents and it role in current era and future roleBiological agents and it role in current era and future role
Biological agents and it role in current era and future role
 
Hepatoprotective and Antioxidant Effects of the Flavonoid-rich Fraction of th...
Hepatoprotective and Antioxidant Effects of the Flavonoid-rich Fraction of th...Hepatoprotective and Antioxidant Effects of the Flavonoid-rich Fraction of th...
Hepatoprotective and Antioxidant Effects of the Flavonoid-rich Fraction of th...
 
new drug development by harsha
new drug development by harshanew drug development by harsha
new drug development by harsha
 
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
 
GENOTOXICITY STUDIES(as per OECD)
GENOTOXICITY STUDIES(as per OECD)GENOTOXICITY STUDIES(as per OECD)
GENOTOXICITY STUDIES(as per OECD)
 
Biopharmaceuticals and biosimilar drugs
Biopharmaceuticals and biosimilar drugsBiopharmaceuticals and biosimilar drugs
Biopharmaceuticals and biosimilar drugs
 
Biosimilars
Biosimilars Biosimilars
Biosimilars
 
Potential role of bioactive peptides in prevention and treatment of chronic d...
Potential role of bioactive peptides in prevention and treatment of chronic d...Potential role of bioactive peptides in prevention and treatment of chronic d...
Potential role of bioactive peptides in prevention and treatment of chronic d...
 
new biological targets by prathyusha .m
new biological targets by prathyusha .mnew biological targets by prathyusha .m
new biological targets by prathyusha .m
 
Pegylation & biosimilars global scenario
Pegylation & biosimilars   global scenarioPegylation & biosimilars   global scenario
Pegylation & biosimilars global scenario
 
Biosimilar : A Biologic Drug Revolution.
Biosimilar : A Biologic Drug Revolution.Biosimilar : A Biologic Drug Revolution.
Biosimilar : A Biologic Drug Revolution.
 
Biosimilars: A biologic drug revolution
Biosimilars: A biologic drug revolutionBiosimilars: A biologic drug revolution
Biosimilars: A biologic drug revolution
 
Biosimilars ppt presentation
Biosimilars ppt presentationBiosimilars ppt presentation
Biosimilars ppt presentation
 
DRUG discovery
DRUG discoveryDRUG discovery
DRUG discovery
 
Immunotoxicity
ImmunotoxicityImmunotoxicity
Immunotoxicity
 
Development mol drug
Development mol drugDevelopment mol drug
Development mol drug
 
Biosimilars in rheumatology
Biosimilars in rheumatologyBiosimilars in rheumatology
Biosimilars in rheumatology
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
Biosimilar
BiosimilarBiosimilar
Biosimilar
 
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
 

Destaque

Intellectual Property Considerations During Nonclinical Drug Development
Intellectual Property Considerations During Nonclinical Drug DevelopmentIntellectual Property Considerations During Nonclinical Drug Development
Intellectual Property Considerations During Nonclinical Drug DevelopmentMaryBreenSmith
 
Zipcar101
Zipcar101Zipcar101
Zipcar101kmorham
 
Curso de crianza
Curso de crianzaCurso de crianza
Curso de crianzaNez Vazkez
 
Curso de crianza pokemon
Curso de crianza pokemonCurso de crianza pokemon
Curso de crianza pokemonNez Vazkez
 
16 12 11_-_sdm_project[1] [modo de compatibilidade]
16 12 11_-_sdm_project[1] [modo de compatibilidade]16 12 11_-_sdm_project[1] [modo de compatibilidade]
16 12 11_-_sdm_project[1] [modo de compatibilidade]Clapbio
 
Excelencias
ExcelenciasExcelencias
ExcelenciasFEARC
 
El peregrino perdido 2
El peregrino perdido 2El peregrino perdido 2
El peregrino perdido 2IES XELMIREZ 1
 
Bluemotif Recent Projects
Bluemotif Recent ProjectsBluemotif Recent Projects
Bluemotif Recent Projectsmellis3060
 
Guide for conducting comparability exercise for biological product registration
Guide for conducting comparability exercise for biological product registrationGuide for conducting comparability exercise for biological product registration
Guide for conducting comparability exercise for biological product registrationClapbio
 
Chile ds 03 eng
Chile ds 03 engChile ds 03 eng
Chile ds 03 engClapbio
 
Japan's Child Care
Japan's Child CareJapan's Child Care
Japan's Child Carekellyyin
 
Guide for elaboration of clinical study reports for biological product regist...
Guide for elaboration of clinical study reports for biological product regist...Guide for elaboration of clinical study reports for biological product regist...
Guide for elaboration of clinical study reports for biological product regist...Clapbio
 
Panama rules
Panama rulesPanama rules
Panama rulesClapbio
 
actividades para Excel
actividades para Excelactividades para Excel
actividades para Excelvariniacrista
 
Presentación mujeres emprendedoras accenture 2016
Presentación mujeres emprendedoras accenture 2016Presentación mujeres emprendedoras accenture 2016
Presentación mujeres emprendedoras accenture 2016FEARC
 

Destaque (20)

Intellectual Property Considerations During Nonclinical Drug Development
Intellectual Property Considerations During Nonclinical Drug DevelopmentIntellectual Property Considerations During Nonclinical Drug Development
Intellectual Property Considerations During Nonclinical Drug Development
 
Zipcar101
Zipcar101Zipcar101
Zipcar101
 
Curso de crianza
Curso de crianzaCurso de crianza
Curso de crianza
 
Curso de crianza pokemon
Curso de crianza pokemonCurso de crianza pokemon
Curso de crianza pokemon
 
Goals
GoalsGoals
Goals
 
16 12 11_-_sdm_project[1] [modo de compatibilidade]
16 12 11_-_sdm_project[1] [modo de compatibilidade]16 12 11_-_sdm_project[1] [modo de compatibilidade]
16 12 11_-_sdm_project[1] [modo de compatibilidade]
 
Excelencias
ExcelenciasExcelencias
Excelencias
 
El peregrino perdido
El peregrino perdidoEl peregrino perdido
El peregrino perdido
 
El peregrino perdido 2
El peregrino perdido 2El peregrino perdido 2
El peregrino perdido 2
 
Japanese
JapaneseJapanese
Japanese
 
Bluemotif Recent Projects
Bluemotif Recent ProjectsBluemotif Recent Projects
Bluemotif Recent Projects
 
Power point
Power pointPower point
Power point
 
Guide for conducting comparability exercise for biological product registration
Guide for conducting comparability exercise for biological product registrationGuide for conducting comparability exercise for biological product registration
Guide for conducting comparability exercise for biological product registration
 
Chile ds 03 eng
Chile ds 03 engChile ds 03 eng
Chile ds 03 eng
 
Who
WhoWho
Who
 
Japan's Child Care
Japan's Child CareJapan's Child Care
Japan's Child Care
 
Guide for elaboration of clinical study reports for biological product regist...
Guide for elaboration of clinical study reports for biological product regist...Guide for elaboration of clinical study reports for biological product regist...
Guide for elaboration of clinical study reports for biological product regist...
 
Panama rules
Panama rulesPanama rules
Panama rules
 
actividades para Excel
actividades para Excelactividades para Excel
actividades para Excel
 
Presentación mujeres emprendedoras accenture 2016
Presentación mujeres emprendedoras accenture 2016Presentación mujeres emprendedoras accenture 2016
Presentación mujeres emprendedoras accenture 2016
 

Semelhante a Guide for conduction of nonclinical and clinical studies for registration of alphainterferon as biological product by comparability development

Future of Biological Drugs
Future of Biological DrugsFuture of Biological Drugs
Future of Biological DrugsSujay Iyer
 
Comparative evaluation study on different brands of lisinopril tablet using h...
Comparative evaluation study on different brands of lisinopril tablet using h...Comparative evaluation study on different brands of lisinopril tablet using h...
Comparative evaluation study on different brands of lisinopril tablet using h...Alexander Decker
 
Phytochemicals ,herbals and dietary supplements
Phytochemicals ,herbals and dietary supplementsPhytochemicals ,herbals and dietary supplements
Phytochemicals ,herbals and dietary supplementssky finances limited
 
Biologicals and biosimilars a review of the science and its implications
Biologicals and biosimilars   a review of the science and its implicationsBiologicals and biosimilars   a review of the science and its implications
Biologicals and biosimilars a review of the science and its implicationsNational Institute of Biologics
 
Guideline on potency testing of cell based immunotherapy medicinal products f...
Guideline on potency testing of cell based immunotherapy medicinal products f...Guideline on potency testing of cell based immunotherapy medicinal products f...
Guideline on potency testing of cell based immunotherapy medicinal products f...National Institute of Biologics
 
Herbal medications and Nutritional supplements
Herbal medications and Nutritional supplementsHerbal medications and Nutritional supplements
Herbal medications and Nutritional supplementsEneutron
 
Reg.IssuesCRO.tripati.ppt
Reg.IssuesCRO.tripati.pptReg.IssuesCRO.tripati.ppt
Reg.IssuesCRO.tripati.pptCchatcha SU
 
Pharmacological evaluation of hepatoprotective activity of Ethanolic extract ...
Pharmacological evaluation of hepatoprotective activity of Ethanolic extract ...Pharmacological evaluation of hepatoprotective activity of Ethanolic extract ...
Pharmacological evaluation of hepatoprotective activity of Ethanolic extract ...pharmaindexing
 
Pharmacological evaluation of hepatoprotective activity of ethanolic extract ...
Pharmacological evaluation of hepatoprotective activity of ethanolic extract ...Pharmacological evaluation of hepatoprotective activity of ethanolic extract ...
Pharmacological evaluation of hepatoprotective activity of ethanolic extract ...pharmaindexing
 
DDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.pptDDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.pptFakhrulAhsan2
 
Drug product performance in-vivo
Drug product performance in-vivoDrug product performance in-vivo
Drug product performance in-vivoSayaliDarekar
 
Introduction to the drug discovery process
Introduction to the drug discovery processIntroduction to the drug discovery process
Introduction to the drug discovery processThanh Truong
 
The totality of-the-evidence approach to the assessment of Erelzi™
The totality of-the-evidence approach to the assessment of Erelzi™The totality of-the-evidence approach to the assessment of Erelzi™
The totality of-the-evidence approach to the assessment of Erelzi™Osaid Al Meanazel
 

Semelhante a Guide for conduction of nonclinical and clinical studies for registration of alphainterferon as biological product by comparability development (20)

Future of Biological Drugs
Future of Biological DrugsFuture of Biological Drugs
Future of Biological Drugs
 
Comparative evaluation study on different brands of lisinopril tablet using h...
Comparative evaluation study on different brands of lisinopril tablet using h...Comparative evaluation study on different brands of lisinopril tablet using h...
Comparative evaluation study on different brands of lisinopril tablet using h...
 
Phytochemicals ,herbals and dietary supplements
Phytochemicals ,herbals and dietary supplementsPhytochemicals ,herbals and dietary supplements
Phytochemicals ,herbals and dietary supplements
 
Regulatory Perspectives on Biosimilars in Europe
Regulatory Perspectives on Biosimilars in EuropeRegulatory Perspectives on Biosimilars in Europe
Regulatory Perspectives on Biosimilars in Europe
 
USFDA NDA Vs BLA
USFDA NDA Vs BLAUSFDA NDA Vs BLA
USFDA NDA Vs BLA
 
Biologicals and biosimilars a review of the science and its implications
Biologicals and biosimilars   a review of the science and its implicationsBiologicals and biosimilars   a review of the science and its implications
Biologicals and biosimilars a review of the science and its implications
 
Promonitor
PromonitorPromonitor
Promonitor
 
Guideline on potency testing of cell based immunotherapy medicinal products f...
Guideline on potency testing of cell based immunotherapy medicinal products f...Guideline on potency testing of cell based immunotherapy medicinal products f...
Guideline on potency testing of cell based immunotherapy medicinal products f...
 
Herbal medications and Nutritional supplements
Herbal medications and Nutritional supplementsHerbal medications and Nutritional supplements
Herbal medications and Nutritional supplements
 
Reg.IssuesCRO.tripati.ppt
Reg.IssuesCRO.tripati.pptReg.IssuesCRO.tripati.ppt
Reg.IssuesCRO.tripati.ppt
 
Pharmacological evaluation of hepatoprotective activity of Ethanolic extract ...
Pharmacological evaluation of hepatoprotective activity of Ethanolic extract ...Pharmacological evaluation of hepatoprotective activity of Ethanolic extract ...
Pharmacological evaluation of hepatoprotective activity of Ethanolic extract ...
 
Pharmacological evaluation of hepatoprotective activity of ethanolic extract ...
Pharmacological evaluation of hepatoprotective activity of ethanolic extract ...Pharmacological evaluation of hepatoprotective activity of ethanolic extract ...
Pharmacological evaluation of hepatoprotective activity of ethanolic extract ...
 
RESEARCH PROJECT
RESEARCH PROJECTRESEARCH PROJECT
RESEARCH PROJECT
 
DDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.pptDDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.ppt
 
31. Immunogenicity of Biologicals: Clinical Consequences
31. Immunogenicity of Biologicals: Clinical Consequences31. Immunogenicity of Biologicals: Clinical Consequences
31. Immunogenicity of Biologicals: Clinical Consequences
 
Drug development
Drug developmentDrug development
Drug development
 
Drug product performance in-vivo
Drug product performance in-vivoDrug product performance in-vivo
Drug product performance in-vivo
 
Biosimilars
BiosimilarsBiosimilars
Biosimilars
 
Introduction to the drug discovery process
Introduction to the drug discovery processIntroduction to the drug discovery process
Introduction to the drug discovery process
 
The totality of-the-evidence approach to the assessment of Erelzi™
The totality of-the-evidence approach to the assessment of Erelzi™The totality of-the-evidence approach to the assessment of Erelzi™
The totality of-the-evidence approach to the assessment of Erelzi™
 

Mais de Clapbio

Position paper brasil_12março2012
Position paper brasil_12março2012Position paper brasil_12março2012
Position paper brasil_12março2012Clapbio
 
Position paper brasil_12março2012_esp
Position paper brasil_12março2012_espPosition paper brasil_12março2012_esp
Position paper brasil_12março2012_espClapbio
 
Gmm vol 148_-_1_2012 (1) cópia
Gmm vol 148_-_1_2012 (1) cópiaGmm vol 148_-_1_2012 (1) cópia
Gmm vol 148_-_1_2012 (1) cópiaClapbio
 
Emea guidelines
Emea guidelinesEmea guidelines
Emea guidelinesClapbio
 
Biosimilars usa
Biosimilars usaBiosimilars usa
Biosimilars usaClapbio
 
Denizar vianna clap_bio_meeting_rio_dec16th2011 [modo de compatibilidade]
Denizar vianna clap_bio_meeting_rio_dec16th2011 [modo de compatibilidade]Denizar vianna clap_bio_meeting_rio_dec16th2011 [modo de compatibilidade]
Denizar vianna clap_bio_meeting_rio_dec16th2011 [modo de compatibilidade]Clapbio
 
16 12 11_sdm_concepts[2] [modo de compatibilidade]
16 12 11_sdm_concepts[2] [modo de compatibilidade]16 12 11_sdm_concepts[2] [modo de compatibilidade]
16 12 11_sdm_concepts[2] [modo de compatibilidade]Clapbio
 
Chile ds 03 eng
Chile ds 03 engChile ds 03 eng
Chile ds 03 engClapbio
 
Who guidelines on evaluation of similar biotherapeutic products (sb ps) – spa...
Who guidelines on evaluation of similar biotherapeutic products (sb ps) – spa...Who guidelines on evaluation of similar biotherapeutic products (sb ps) – spa...
Who guidelines on evaluation of similar biotherapeutic products (sb ps) – spa...Clapbio
 
Regul. panamá
Regul. panamáRegul. panamá
Regul. panamáClapbio
 
Norma pbs 8 2 chile
Norma pbs 8 2 chileNorma pbs 8 2 chile
Norma pbs 8 2 chileClapbio
 
Decreto oct 2011 mx
Decreto   oct 2011 mxDecreto   oct 2011 mx
Decreto oct 2011 mxClapbio
 
7075 11 iname establece requisitos para registro de especialidades medicina...
7075 11 iname   establece requisitos para registro de especialidades medicina...7075 11 iname   establece requisitos para registro de especialidades medicina...
7075 11 iname establece requisitos para registro de especialidades medicina...Clapbio
 
Technical note about biological products 19 10 11
Technical note about biological products 19 10 11Technical note about biological products 19 10 11
Technical note about biological products 19 10 11Clapbio
 
Argentina rules
Argentina rulesArgentina rules
Argentina rulesClapbio
 
Produtos biologicos exercicio
Produtos biologicos exercicioProdutos biologicos exercicio
Produtos biologicos exercicioClapbio
 
Produtos biologicos
Produtos biologicosProdutos biologicos
Produtos biologicosClapbio
 
Interferon
InterferonInterferon
InterferonClapbio
 
Heparina
HeparinaHeparina
HeparinaClapbio
 

Mais de Clapbio (20)

Position paper brasil_12março2012
Position paper brasil_12março2012Position paper brasil_12março2012
Position paper brasil_12março2012
 
Position paper brasil_12março2012_esp
Position paper brasil_12março2012_espPosition paper brasil_12março2012_esp
Position paper brasil_12março2012_esp
 
Gmm vol 148_-_1_2012 (1) cópia
Gmm vol 148_-_1_2012 (1) cópiaGmm vol 148_-_1_2012 (1) cópia
Gmm vol 148_-_1_2012 (1) cópia
 
Emea guidelines
Emea guidelinesEmea guidelines
Emea guidelines
 
Biosimilars usa
Biosimilars usaBiosimilars usa
Biosimilars usa
 
Denizar vianna clap_bio_meeting_rio_dec16th2011 [modo de compatibilidade]
Denizar vianna clap_bio_meeting_rio_dec16th2011 [modo de compatibilidade]Denizar vianna clap_bio_meeting_rio_dec16th2011 [modo de compatibilidade]
Denizar vianna clap_bio_meeting_rio_dec16th2011 [modo de compatibilidade]
 
16 12 11_sdm_concepts[2] [modo de compatibilidade]
16 12 11_sdm_concepts[2] [modo de compatibilidade]16 12 11_sdm_concepts[2] [modo de compatibilidade]
16 12 11_sdm_concepts[2] [modo de compatibilidade]
 
Chile ds 03 eng
Chile ds 03 engChile ds 03 eng
Chile ds 03 eng
 
Who guidelines on evaluation of similar biotherapeutic products (sb ps) – spa...
Who guidelines on evaluation of similar biotherapeutic products (sb ps) – spa...Who guidelines on evaluation of similar biotherapeutic products (sb ps) – spa...
Who guidelines on evaluation of similar biotherapeutic products (sb ps) – spa...
 
Regul. panamá
Regul. panamáRegul. panamá
Regul. panamá
 
Norma pbs 8 2 chile
Norma pbs 8 2 chileNorma pbs 8 2 chile
Norma pbs 8 2 chile
 
Decreto oct 2011 mx
Decreto   oct 2011 mxDecreto   oct 2011 mx
Decreto oct 2011 mx
 
7075 11 iname establece requisitos para registro de especialidades medicina...
7075 11 iname   establece requisitos para registro de especialidades medicina...7075 11 iname   establece requisitos para registro de especialidades medicina...
7075 11 iname establece requisitos para registro de especialidades medicina...
 
Technical note about biological products 19 10 11
Technical note about biological products 19 10 11Technical note about biological products 19 10 11
Technical note about biological products 19 10 11
 
Argentina rules
Argentina rulesArgentina rules
Argentina rules
 
Produtos biologicos exercicio
Produtos biologicos exercicioProdutos biologicos exercicio
Produtos biologicos exercicio
 
Produtos biologicos
Produtos biologicosProdutos biologicos
Produtos biologicos
 
Interferon
InterferonInterferon
Interferon
 
Heparina
HeparinaHeparina
Heparina
 
Oms
OmsOms
Oms
 

Último

Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023Steve Rader
 
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView
 
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003believeminhh
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBBPMedia1
 
Six Sigma Improvement Process: Transforming Processes, Elevating Performance
Six Sigma Improvement Process: Transforming Processes, Elevating PerformanceSix Sigma Improvement Process: Transforming Processes, Elevating Performance
Six Sigma Improvement Process: Transforming Processes, Elevating PerformanceOperational Excellence Consulting
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxWorkforce Group
 
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...Khaled Al Awadi
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGlokeshwarmaha
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsyasinnathani
 
Human Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and AppraisalHuman Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and Appraisalgomezdominic3
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHelene Heckrotte
 
Transform Your Kitchen Essential Tips for Renovations in Launceston
Transform Your Kitchen Essential Tips for Renovations in LauncestonTransform Your Kitchen Essential Tips for Renovations in Launceston
Transform Your Kitchen Essential Tips for Renovations in Launcestondjhbuildersau
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examplesamberjiles31
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfJohnCarloValencia4
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.mcshagufta46
 
Project Brief & Information Architecture Report
Project Brief & Information Architecture ReportProject Brief & Information Architecture Report
Project Brief & Information Architecture Reportamberjiles31
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinAnton Skornyakov
 

Último (20)

Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
 
Deira Dubai Call Girls +971552825767 Call Girls In Downtown Dubai
Deira Dubai Call Girls +971552825767 Call Girls In Downtown DubaiDeira Dubai Call Girls +971552825767 Call Girls In Downtown Dubai
Deira Dubai Call Girls +971552825767 Call Girls In Downtown Dubai
 
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
 
WAM Corporate Presentation Mar 25 2024.pdf
WAM Corporate Presentation Mar 25 2024.pdfWAM Corporate Presentation Mar 25 2024.pdf
WAM Corporate Presentation Mar 25 2024.pdf
 
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
The Vietnam Believer Newsletter_MARCH 25, 2024_EN_Vol. 003
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
 
Six Sigma Improvement Process: Transforming Processes, Elevating Performance
Six Sigma Improvement Process: Transforming Processes, Elevating PerformanceSix Sigma Improvement Process: Transforming Processes, Elevating Performance
Six Sigma Improvement Process: Transforming Processes, Elevating Performance
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
 
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...
 
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story points
 
Human Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and AppraisalHuman Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and Appraisal
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
 
Transform Your Kitchen Essential Tips for Renovations in Launceston
Transform Your Kitchen Essential Tips for Renovations in LauncestonTransform Your Kitchen Essential Tips for Renovations in Launceston
Transform Your Kitchen Essential Tips for Renovations in Launceston
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examples
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.
 
Project Brief & Information Architecture Report
Project Brief & Information Architecture ReportProject Brief & Information Architecture Report
Project Brief & Information Architecture Report
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup Berlin
 

Guide for conduction of nonclinical and clinical studies for registration of alphainterferon as biological product by comparability development

  • 1. Guide for conduction of nonclinical and clinical studies for registration of alpha- interferon as biological product by comparability development
  • 2. National Health Surveillance Agency | Anvisa Guide for Conduction of Nonclinical and Clinical Studies for Registration of Alpha-Interferon as Biological Product by Comparability Development Brasilia 2011
  • 3. Copyright © 2011. National Health Surveillance Agency. Partial or full reproduction of this works is allowed provided the source is mentioned. Legal deposit in the National Library, according to Decree No. 1.825, dated December 20, 1907. 1st edition. CEO CEO’s Assistant Dirceu Aparecido Brás Barbano Luiz Roberto da Silva Klassmann Directors Directors’ Assistants Jaime César de Moura Oliveira Luciana Shimizu Takara José Agenor Álvares da Silva Neilton Araujo de Oliveira Maria Cecília Martins Brito Luiz Armando Erthal Head of Cabinet Vera Maria Borralho Bacelar General Drug Management Norberto Rech Safety & Efficacy Assessment Management Laura Gomes Castanheira Biological Product Registration Coordination Marcelo Mário Matos Moreira Direct participation: Brenda Gomes Valente Bernardo Luiz Moraes Mo reira Fanny Nascimento Moura Flávia Regina Souza Sobral Daniela Marreco Cerqueira Juliana Bertoli da Silva Laura Gomes Castanheira Marcelo Mário Matos Mo reira Marcos Fernando Galves da Silva Maria Fernanda Reis e Silva Thees Neemias Silva de Andrade Patrícia Ferrari Andreotti Raimundo Nonato Vieira Júnior Rodrigo Martins Bretas Silmara Crisitane da Silveira Elaboration and editing AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA SIA Trecho 5, Área Especial 57, Lote 200 71205-050, Brasilia – Federal District Phone: (61) 3462-6000 Home page: www.anvisa.gov.br
  • 4. Table of contents 1 Introduction.................................................................................................................................................... 4 2 General Considerations ...................................................................................................................................4 3 Nonclinical studies.....................................................................................................................................5 4 Clinical studies ...........................................................................................................................................6 5 Immunogenicity ..........................................................................................................................................7 6 Indication Extrapolation..........................................................................................................................7 7 Pharmacovigilance Plan ..........................................................................................................................7 8 References .................................................................................................................................................8 Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability 3
  • 5. 1 Introduction This guide outlines the clinical and nonclinical requirements for registration of recombinant human alpha-interferon in Anvisa [National Health Surveillance Agency] as biological product, using the route of individual development. The nonclinical section deals with the pharmaco-toxicological requirements, and the clinical section addresses the requirements for pharmacokinetic, pharmacodynamics, efficacy and safety studies, as well as pharmacovigilance aspects. Suggestions of nonclinical and clinical protocols are also presented. In this guide, we will bring general directions for the conduction of nonclinical and clinical studies for registration of recombinant human alpha-interferon by comparability. However, if the researcher/institution is able to evidence the efficacy and safety of these drugs through other scientific and technically more feasible studies, the data presented will be evaluated by ANVISA and the deviation from the guide’s directions must always be justified. This Guide will address only the requirements for nonclinical and clinical studies applicable for registration of recombinant human alpha-interferon by comparability, being that the other items of the specific standards must be complied with for health registration of the product. 2 General considerations Recombinant human alpha-interferon (2a a n d 2 b ) i s a known and well characterized protein made up of 165 amino acids. The non-glycosylated protein has a molecular weight of approximately 19.240 Da. The protein contains two disulfide bridges, one between the cysteine residues 1 and 98 and another between the cysteine residues 29 and 138. The sequence contains potential O-glycosylation sites. Physical, chemical and biological methods are available for protein characterization. Recombinant human alpha-interferon is approved for different indications like hepatitis virus B and C, leukemia, lymphoma, renal cell carcinoma and multiple myeloma and can be used separately or in combination with other drugs. Alpha-interferon can have different pharmacodynamics effects. The importance of these pharmacodynamics effects in each one of the clinical applications is still unknown. Generally, the use of alpha-interferon in oncology has reduced considerably and is being replaced by other treatments. The dose and therapeutic scheme required to obtain the desired response vary greatly according to the different indications. Alpha-interferon is normally used subcutaneously, although it can also be used intramuscularly or intravenously. Treatment with alpha-interferon 2a and 2b is associated with different adverse reactions like fever, discomfort, fatigue, myalgia and can also be associated with psychiatric, hematological and renal adverse events. Therapy with alpha-interferon can lead to development of auto-antibodies. A variety of autoimmune disorders like problems in the thyroid, rheumatoid arthritis, systemic erythematous lupus, neuropathies and vasculitis have been observed with the use of alpha- interferon. Both neutralizing and non-neutralizing antibodies were observed during use of alpha-interferon. This guide does not address the quality requirements. For aspects related to quality, the principles are applied as set forth in the Guide for conduction of the comparability exercise for registration of biological products by comparability and Resolution RDC No. 55/10 and its updates. According to RDC 55/10, the comparer biological product (CBP) cited in this guide is recombinant human alpha-interferon registered at Anvisa through presentation of a complete dossier.
  • 6. 4 Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability
  • 7. 3 Nonclinical studies Before starting the clinical development, nonclinical studies must be conducted. The nonclinical studies must be comparative and designed to detect differences in the pharmaco-toxicological response between the alpha-interferon to be registered and the CBP, and not just to evaluate the response per se. The approach adopted must be fully justified in the nonclinical summary. Pharmacodynamic studies In vitro studies: In order to compare the changes in the activity between the alpha-interferon to be registered and the CBP, one must provide data on a series of comparative bioassays (bond with receptor, antiviral effect in cell culture, anti-proliferative effects in tumor cell lineages), being that several of these assays will already be part of the quality dossier in the comparability exercise. In vivo studies: One must compare the in vivo pharmacodynamics activity of the alpha-interferon to be registered and of the CBP in: • a suitable animal pharmacodynamics model (e.g. evaluation of the effects on pharmacodynamics markers, like 2’-5’- oligoadenylate synthetase activity in the serum). If possible, these evaluations must be conducted as part of a toxicity study. and/ or • suitable tumor animal model and/or • suitable antiviral animal model Toxicology Studies Data on at least one repeated dose toxicity study in relevant species must be provided. The study must have duration of at least 4 weeks. Toxicokinetic studies must be conducted as part of the repeated dose toxicity study and must include evaluation of the antibody formation potential. Data on the local tolerance in at least one species must be provided. If possible, these local tolerance tests can be conducted as part of a repeated-dose toxicity study. E Pharmacological studies on safety, reproductive toxicology, mutagenicity and carcinogenicity are not routine requirements for the nonclinical tests of a biological drug product containing recombinant human alpha-interferon. For the case of nonclinical development, comparative studies must be conducted using the alpha-interferon elected as comparer product (alpha-interferon registered at Anvisa through presentation of a complete dossier) and the alpha-interferon to be registered. At least two relevant species should be used if available and local tolerance, acute toxicity and repeated dose toxicity studies must be conducted. Comparative evaluation of pharmacokinetic, pharmacodynamics and immunogenicity (whenever possible) parameters are also required. Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability 5
  • 8. 4 Clinical studies Pharmacokinetic/Pharmacodynamic Studies The pharmacokinetic/pharmacodynamics properties of the alpha-interferon to be registered and of the CBP must be compared in a randomized, single-dose study in health volunteers. The primary pharmacokinetic parameters recommended are area under the curve (AUC) and the secondary parameters are Cmax, T1/2 and CL/F. The equivalence margins must be pre-specified and appropriately justified. Pharmacodynamic Studies: Different pharmacodynamics markers are available, like β2 microglobulin, neopterin and 2’-5’- oligoadenylate synthetase activity in the serum, which are relevant to measure the interaction between alpha-interferon and the immune system. The doses selected must be in the ascending linear region of the dose response curve. Even though the importance of these pharmacodynamics effects is still unknown in the different indications, a complete comparative evaluation after administration of epoetin alpha to be registered and the CBP can provide useful data. After conducting the necessary nonclinical studies with satisfactory results, the conduction of a Phase I, comparative, double-blind study is recommended with health volunteers and a wash-out period of 4 weeks. The aim of this study is comparison of the pharmacokinetic and pharmacodynamics parameters and gathering of preliminary safety data. Clinical Efficacy Study population The action mechanism of alpha-interferon includes a series of different unrelated effects. Demonstration of effect similarity between the product to be registered and the CBP is required. This can be done in a virgin population of treatment with hepatitis C (HCV), as outlined by the indication of the CBP. Other populations must be studied according to the indications desired. Study outlining and duration A parallel, randomized group study for comparison of the products for at least 48 weeks is recommended. The study must be double- blind at least up to the point in which the data from the primary analyses is generated. If this is not possible, a justification must be presented and all actions to eliminate possible biases must be clearly identified in the protocol. The posology (dose, administration route and administration methodology) must be the same as for the CBP. The alpha-interferon must be administered together with the standard treatment for hepatitis C used together with the CBP. The study must be outlined so as to allow conduction of the primary efficacy analysis in the twelfth week for all recruited patients. A homogeneous population is preferably recommended, for example, a single viral genotype. If a heterogeneous population is selected, stratification must be conducted according to the viral genotype. Outcomes Primary: virological response evaluated by the number of patients with absence of HCV RNA detection by quantitative PCR in the twelfth week. The methodology used and the cutoff applied must be justified. A decrease of 2 log in the viral growth must have a co- primary outcome. Secondary: virological response in the fourth week and at the end of treatment; sustained virological response (24 weeks after the end of treatment); changes in the hepatic biochemical parameters including levels of transaminase and morbidity. 6 Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability
  • 9. Clinical safety The safety data must be collected from the patients after repeated doses in a comparative study during the treatment period and another period of 24 weeks of follow-up. The number of patients must be enough for comparison of the adverse effect profiles. Evaluation of lab changes of immune-mediated disorders must be included. The safety profile between the alpha-interferon to be registered and the CBP must be similar for the most common adverse events (fever, discomfort, alopecia, myalgia, leukopenia, anemia and thrombocytopenia). If the results of the Phase I Study are satisfactory, a Phase II/III study can be conducted to evaluate the efficacy and safety of the alpha-interferon to be registered in relation to the comparer biological product. It must be a double-blind study to compare non-inferiority or equivalence in patients with Hepatitis C and have minimum duration of 48 weeks. The primary outcome of the study must be viral remission (evaluated through quantitative PCR) in the 24th week and the secondary outcomes will be virological response in the 4th, 12th and 48th weeks (evaluated through quantitative PCR); biochemical parameters must also be evaluated (including transaminases) and morbidity levels. Evaluation of safety (type, severity and incidence of adverse events) and of immunogenicity must be done for the period of the study duration (48 weeks). In case of any significant finding in relation to the safety and immunogenicity parameters, additional studies may be requested. 5 Immunogenicity Comparative data on immunogenicity (levels of antibodies) must be collected during the study period and also during the 24-week follow-up period. The antibodies, when present, must be evaluated for neutralizing capacity and potential impact on product efficacy. Furthermore, any potential for neutralization of the alpha-interferon’s endogenous effect (development of autoimmunity) must be evaluated. Any immunogenicity impact must be evaluated in patients who do not respond to the treatment, patients who present loss of response in the primary treatment and patients who present unexpected adverse reactions or immune-mediated events. 6 Indication Extrapolation At first, the extrapolation of therapeutic indications is possible when the action mechanism and/or receptors are the same for which the clinical similarity was established, through comparative clinical study. 7 Pharmacovigilance Plan Within the authorization procedure, the applicant must always present a pharmacovigilance plan and a risk reduction plan whenever required according to the legislation in effect and pharmacovigilance guidelines. Special attention must be paid to issues related to immunogenicity and later serious adverse effects in patients under chronic administration of the product. Safety data must be gathered from patients covering all approved indications. The Pharmacovigilance Plan must include follow-up of the patients included in the Phase II/III study for evaluation of relapses. Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability 7
  • 10. 8 References Guideline on similar biological medicinal products (CHMP/437/04/draft). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CPMP/42832/05/draft). Note for guidance on repeated dose toxicity (CPMP/SWP/1042/99). Note for guidance on toxicokinetics: A Guidance for assessing systemic exposure in toxicological studies (CPMP/ICH/384/95). Note for guidance on non-clinical locale tolerance testing of medicinal products (CPMP/SWP/2145/00). Guideline on risk management systems for medicinal products for human use (EMEA/CHMP 96286/2005). Note for Guidance on Good Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/ ICH/377/95). ICH Note for Guidance on Planning Pharmacovigilance Activities (CPMP/ICH/5716/03 - Final approval by CHMP on PHV). Guidance on Planning Pharmacovigilance Activities (CPMP/ 8 Guide for conduction of nonclinical and clinical studies for registration of heparins as biological product in development by comparability
  • 11. Ministry of Health